Carolina Liquid Chemistries Corp. (CLC) has entered into a distribution agreement with Medline Industries, LP (Medline) to make one of the first FDA-cleared, point-of-care fentanyl screening test kits readily available to many point-of-care sites and clinical laboratories across the United States of America.
The test kit, called Fentanyl Urine Detect, is intended for the qualitative detection of fentanyl in human urine at a cutoff concentration of 1.0 ng/mL with a result in under six minutes. The test is used in conjunction with Carolina Liquid Chemistries’ RYAN immunofluorescence analyzer and can produce a printed, chartable result that is interfaceable with laboratory information systems (LIS). The test provides a preliminary result; a more specific alternative chemical method must be used in order to obtain a confirmed analytical result.
The RYAN analyzer is a fluorescence instrument for in vitro diagnostic tests on clinical urine specimens. Weighing less than five pounds, this portable analyzer can be used in a laboratory or in a point-of-care setting. To learn more about Fentanyl Urine Detect on the immunofluorescence analyzer RYAN, please visit https://www.carolinachemistries.com/products/fentanyl-urine-detect-on-clc-ryan-analyzer/
